A Clinical Analysis of Optimal Therapeutics to Improve Outcomes in Patients with Advanced Prostate Cancer

Program Overview

This CE program will analyze optimal therapeutics for the treatment and management of prostate cancer patients, incorporating data presented at the American Society of Clinical Oncology 2018 Genitourinary (GU) Cancers Symposium in San Francisco, California. The three expert faculty, led by Dr. Elisabeth Heath, will review the framework for clinical decision making in prostate cancer. Recent clinical trial data for metastatic and non-metastatic castration-resistant prostate cancer (CRPC) as well as castration-sensitive prostate cancer (CSPC) will be reviewed and clinical relevance debated. The faculty will relay best practices for utilizing the interprofessional team to reduce adverse events and improve quality of life in this patient population. At the conclusion of this discussion-based activity, learners will gain better insight into the emerging and emerged techniques for treating and managing patients with prostate cancer.

Target Audience

Oncologists, internists, nurse practitioners, nurses, and other healthcare professionals involved in the management of patients with prostate cancer.

Learning Objectives

  1. Discuss the pathophysiology of prostate cancer in context of the disease progression model
  2. Analyze clinical trial data for current and emerging therapeutics for the treatment of advanced prostate cancer
  3. Implement the interprofessional team approach to develop individualized treatment plans and improve outcomes in patients with prostate cancer


Screen Shot 2018-05-24 at 1.43.01 PMElisabeth I. Heath, MD
Associate Center Director, Translational Sciences
Hartmann Endowed Chair for Prostate Cancer Research
Professor of Oncology
Karmanos Cancer Institute
Wayne State University School of Medicine
Detroit, Michigan



Screen Shot 2018-05-24 at 1.40.24 PMHimisha Beltran, MD
Associate Professor of Medicine
New York–Presbyterian Hospital
Director of Clinical and Translational Research
Englander Institute for Precision Medicine
Weill Cornell Medicine
New York, New York


Screen Shot 2018-05-24 at 1.39.35 PMMichael J. Morris, MD
Prostate Cancer Section Chief
Genitourinary Oncology
Memorial Sloan Kettering Cancer Center
Weill Cornell Medicine
New York, New York




Disclosures of Conflict of Interest

It is the policy of AcademicCME that all faculty, instructors, and planners disclose real or apparent conflicts of interest relating to the topics of this educational activity.

The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CE activity:

FacultyRelationship Identified With:
Elisabeth I. Heath, MD (Chair)Nothing to disclose
Himisha Beltran, MDConsultant/Advisor: AbbVie Inc.; Janssen Pharmaceuticals, Inc.; SanofiGrant/Research Support: AbbVie Inc.; Astellas Pharma US, Inc.; Eli Lilly and Company; Janssen Pharmaceuticals, Inc.
Michael J. Morris, MD Consultant/Advisor: Advanced Accelerator Applications

Planners, Managers, Reviewers

Timothy Hayes, MD, PhD; Emma Boring; Nicole Brestowski and Kim Cheramie, MSN, RN-BC hereby state that they or their spouse/life partner do not have any financial relationships to products or devices with any commercial interests related to the content of this activity of any amount during the past 12 months.

Accreditation Statement

AcademicCME is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

AcademicCME is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center’s Commission on Accreditation.

Credit Designation Statement

AcademicCME designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

AcademicCME designates this enduring material for a maximum of 1.0 CNE contact hour (1.0 CNE pharmacotherapeutic contact hour).

Financial Support

This activity has been supported by an independent educational grant from Sanofi Genzyme.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. AcademicCME and Sanofi Genzyme do not recommend the use of any agent outside of the labeled indications.


Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Method of Participation

  1. Read the learning objectives, accreditation information and faculty disclosures at the beginning of this activity.
  2. Complete the Pre-Activity Questions.
  3. Read or Review the activity content.
  4. Complete the Post-Activity Test Questions and Evaluation.
  5. Healthcare providers who receive a grade of 70% or better on the Post-Activity Test Questions and who complete the Evaluation will receive a CME/CNE Certificate.
  6. All other participants who receive a grade of 70% or better on the Post-Activity Test Questions and who complete the Evaluation will receive a Certificate of Participation.
  7. Healthcare providers should claim only the credit commensurate with the extent of their participation in the activity.
  8. 60 minutes of participation = 1 CNE contact hour

CE Inquiries/Special Needs

For all CME/CNE inquiries or special needs, please contact [email protected].